- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
In The Literature: TNF-α Antagonists in RA Patients Reduces Cancer Risk
A Taiwan study found a significantly reduced risk of cancer among RA patients on biologics.
A nationwide study, conducted in Taiwan between 1999-2011 using the Taiwan National Health Insurance Research Database, compared the risk of cancer diagnosis in patients with rheumatoid arthritis who were administered the TNF-α antagonists versus non-biological disease-modifying anti-rheumatic drugs (nbDMARDs). The study identified a significantly reduced incidence rate of cancer among patients using biologics, and modified Cox proportional hazards analysis showed a much lower risk in the biologics cohort of 4426 users of TNF-α antagonists (HR 0.63, 95% CI 0.49—0.80, P <.001). There was however an increased risk of hematological cancers in the biologics cohort.
Link to the paper in Arthritis Research and Therapy: http://bit.ly/1uVJHWe
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
